Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Blinatumomab and Inotuzumab Ozogamicin in B-ALL
NCT06985485Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- scFv Fragments, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab, inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL), sponsored by First Affiliated Hospital of Soochow University. Started May 2025; status: recruiting.
02
Drugs
blinatumomabinotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06985485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06985485.